Human Metabolome Technologies Reports Profit Decline but Maintains Strong Equity Base

An update from Human Metabolome Technologies, Inc. ( (JP:6090) ) is now available.

Human Metabolome Technologies, Inc., a metabolomics-focused life-science company listed on the Tokyo Stock Exchange Standard market, provides analytical technologies and services that support research and diagnostics applications. Its business model centers on specialized metabolome analysis, targeting institutions and clients that require high-precision biochemical data to advance healthcare and biotechnology solutions.

For the six months ended December 2025, the company reported net sales of ¥659 million, down 3.7% year on year, with operating profit sliding 55.2% to ¥46 million and profit attributable to owners of parent falling 52.9% to ¥43 million. Despite the profit decline, Human Metabolome Technologies maintained a solid financial base, with total assets of ¥2.14 billion, an equity ratio of 84.6%, and stable net assets, though it did not declare a first-quarter dividend for the fiscal year ending June 2026.

The most recent analyst rating on (JP:6090) stock is a Hold with a Yen758.00 price target. To see the full list of analyst forecasts on Human Metabolome Technologies, Inc. stock, see the JP:6090 Stock Forecast page.

More about Human Metabolome Technologies, Inc.

Human Metabolome Technologies, Inc. is listed on the Tokyo Stock Exchange Standard market and operates in the general business category within Japan. The company focuses on metabolome-related technologies and services, positioning itself as a specialized life-science player serving research and commercial customers that rely on detailed metabolic analysis and related solutions.

Average Trading Volume: 10,070

Technical Sentiment Signal: Buy

Current Market Cap: Yen4.12B

For an in-depth examination of 6090 stock, go to TipRanks’ Overview page.